ZNTL · Zentalis Pharmaceuticals
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.
Market Cap
133.6M
52 Wk Range
$1.30 - $6.95
Previous Close
$1.36
Open
$1.33
Volume
1,462,137
Day Range
$1.33 - $1.50
Enterprise Value
-62.81M
Cash
228.9M
Avg Qtr Burn
-32.71M
Insider Ownership
21.05%
Institutional Own.
69.80%
Qtr Updated
Sep 30th 2026
